Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy

Published:2014-02-18 Issue:9 Volume:111 Page:3550-3555
ISSN:0027-8424
Container-title:Proceedings of the National Academy of Sciences
language:en
Short-container-title:Proc Natl Acad Sci USA

Author:

Gibbons Don L.,Pricl Sabrina,Posocco Paola,Laurini Erik,Fermeglia Maurizio,Sun Hanshi,Talpaz Moshe,Donato Nicholas,Quintás-Cardama Alfonso

Publisher

Proceedings of the National Academy of Sciences

Subject

Multidisciplinary

Reference52 articles.

1. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

2. Deininger M, et al. (2009) International randomized study of interferon vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 114(22):1126 (abstr).

3. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

4. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

5. Minimal Residual Disease in Chronic Myeloid Leukemia

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study;BMC Research Notes;2024-04-20

2. Resistance mutations in CML and how we approach them;Hematology;2023-12-08

3. Derivates of 1,6-dihyadroazaazulenes as inhibitors of tyrosine kinases BCR-ABL1 wild type and mutant T315I: a molecular dynamics approach;Journal of Biomolecular Structure and Dynamics;2023-11-08

4. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia;Leukemia;2023-10-04

5. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations;Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3